Sakar Healthcare Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Low debt relative to equity (D/E 0.2x)
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
SAKAR · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 53.15% | 53.15% | 53.15% | 53.15% | 53.58% | 53.58% |
| FII | 13.76% | 13.52% | 13.52% | 13.42% | 13.58% | 13.61% |
| DII | 10.62% | 10.62% | 10.62% | 10.62% | 10.88% | 10.97% |
| Public | 22.47% | 22.71% | 22.71% | 22.80% | 21.96% | 21.85% |
Latest News
All newsSakar Healthcare reports Q2FY26 financial results
*Sakar Healthcare reports Q2FY26 financial results*. The company has submitted its financial results for the quarter ended September 30, 2026. No major deviations or surprises were disclosed in the filing. Results were in line with routine quarterly reporting. 📊 *STOCKS:* $SAKAR | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #Earnings
Sakar Healthcare reports unaudited results for Q2 and H1 FY27
*Sakar Healthcare reports unaudited results for Q2 and H1 FY27*. The company released its consolidated and standalone financial performance for the quarter and half year ended September 30, 2026. Results include key metrics like revenue and profit, though specific figures are not detailed in the press announcement. Traders may await management commentary on outlook and margins. 📊 *STOCKS:* $SAKARHEALTH | 🏢 *SECTOR:* Healthcare | #MEDIUMIMPACT #Earnings
Sakar Healthcare gets EU, UK, Canada approvals for new products
*Sakar Healthcare gets EU, UK, Canada approvals for new products* — The company has secured new regulatory approvals for its medical devices in Europe, the UK, and Canada. These clearances are tied to collaborations with **7 business partners**, boosting its global footprint. The development supports future revenue diversification and international market penetration. 📊 *STOCKS:* SAKARHEALTH | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Approvals
Sakar Healthcare shares up on investor presentation
*Sakar Healthcare shares see interest after investor presentation.* The company filed an investor presentation with the NSE, highlighting business updates and strategic direction. No major financial figures or announcements were disclosed. Volume rose **2.5x** above average. 📊 *STOCKS:* $SAKARHEALTH | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorPresentation
Sakar Healthcare issues general corporate updates
*Sakar Healthcare issues general corporate updates.* The company filed routine disclosures with the NSE, including minor operational and administrative updates. No financial figures or strategic developments were disclosed. Details remain sparse and investor-relevant impact is limited. 📊 *STOCKS:* $SAKAR | 🏢 *SECTOR:* CapitalMarkets | #LOWIMPACT #corporate
Sakar Healthcare files regulatory update for Q3 2026
*Sakar Healthcare files regulatory update for Q3 2026*. The company submitted its disclosure under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. This is a routine compliance requirement with no financial impact. No material changes reported. 📊 *STOCKS:* $SAKARHEALTH | 🏢 *SECTOR:* CapitalMarkets | #LOWIMPACT #Regulatory
Sakar Healthcare to hold shareholder meeting on Sept 22, 2026
*Sakar Healthcare to hold a shareholder meeting on September 22, 2026.* The event is scheduled for routine corporate disclosures and governance. No financial figures or strategic shifts were disclosed. Such meetings typically precede major announcements but lack immediate trading cues. 📊 *STOCKS:* $SAKARHEALTH | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ShareholderMeeting
Sakar Healthcare to hold shareholder meeting on September 22, 2026
*Sakar Healthcare to hold shareholder meeting on September 22, 2026.* The event is scheduled for discussions on corporate matters. No financial figures or strategic announcements disclosed yet. Typically routine in nature, such meetings rarely trigger immediate trading moves. 📊 *STOCKS:* $SAKARHEALTH | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ShareholderMeeting
Sakar Healthcare hosts investor call for updates
*Sakar Healthcare hosts investor call for updates.* The company held an analyst and institutional investor meet to discuss business performance and strategic developments. Specific financial figures or major announcements were not disclosed. The event aimed to enhance investor engagement and transparency. 📊 *STOCKS:* $SAKARCHEM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorCall
Sakar Healthcare shares up on investor presentation
*Sakar Healthcare shares reacted positively following its investor presentation.* The filing indicates increased investor outreach but reveals no major financial updates or strategic announcements. Trading volume rose moderately with **no significant price swing** observed. The stock remains in accumulation phase with **low institutional visibility**. 📊 *STOCKS:* SAKARHEALTH | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorPresentation